The safety of treatments used in pyoderma gangrenosum

References

• Langan SM, Groves RW, Card TR, et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012 Sep;132(9):2166–2170. DOI:10.1038/jid.2012.130.
   PubMed Web of Science ®Google Scholar
• Wollina U. Pyoderma gangrenosum – a review. Orphanet J Rare Dis. 2007;2:19.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Fanoni D, Antiga E, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014 Oct;178(1):48–56. Erratum in: Clin Exp Immunol. 2015 Jul;181(1):188. DOI:10.1111/cei.12394.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2017 Jun;176(6):1588–1598. DOI:10.1111/bjd.15226.
   PubMed Web of Science ®Google Scholar
• Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment. Am J Clin Dermatol. 2017 Aug;18(4):555–562. Review. DOI:10.1007/s40257-017-0265-1.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Borghi A, Meroni PL, et al. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016 Nov; 175(5):882–891. DOI:10.1111/bjd.14691.
   PubMed Web of Science ®Google Scholar
• Thomas KS, Ormerod AD, Craig FE, et al.; UK Dermatology Clinical Trials Network’s STOP GAP Team. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study. J Am Acad Dermatol. 2016 Nov;75(5):940–949. DOI:10.1016/j.jaad.2016.06.016.s.
   PubMed Web of Science ®Google Scholar
• Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005 Aug;53(2):273–283.
   PubMed Web of Science ®Google Scholar
• Lyon CC, Stapleton M, Smith AJ, et al. Topical tacrolimus in the management of peristomal pyoderma gangrenosum. J Dermatolog Treat. 2001 Mar;12(1):13–17.
   PubMed Web of Science ®Google Scholar
• Kiiski V, Remitz A, Reitamo S, et al. Long-term safety of topical pimecrolimus and topical tacrolimus in atopic blepharoconjunctivitis. JAMA Dermatol. 2014 May;150(5):571–573.
   PubMed Web of Science ®Google Scholar
• Rokni GR, Golpour M, Gorji AH, et al. Effectiveness and safety of topical tacrolimus in treatment of vitiligo. J Adv Pharm Technol Res. 2017 Jan-Mar;8(1):29–33. DOI:10.4103/2231-4040.197388.
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Abuabara K, Hoffstad OJ, et al. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2015 Jun;151(6):594–599. DOI:10.1001/jamadermatol.2014.4305.
   PubMed Web of Science ®Google Scholar
• Wollina U. Letter to the editor: temporary renal insufficiency associated with topical tacrolimus treatment of multilocal pyoderma gangrenosum. J Dermatol Case Rep. 2013;7(3):106–107. DOI:10.3315/jdcr.2013.1154.
   PubMedGoogle Scholar
• Cohen PR. Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol. 2009;105:301–312. Review. DOI:10.2165/11310730-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Funayama Y, Kumagai E, Takahashi K, et al. Early diagnosis and early corticosteroid administration improves healing of peristomal pyoderma gangrenosum in inflammatory bowel disease. Dis Colon Rectum. 2009 Feb;52(2):311–314. DOI:10.1007/DCR.0b013e31819accc6.
   PubMed Web of Science ®Google Scholar
• Ormerod AD, Thomas KS, Craig FE, et al.; UK Dermatology Clinical Trials Network’s STOP GAP Team. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015 Jun 12;350:h2958. DOI:10.1136/bmj.h2958.
   PubMed Web of Science ®Google Scholar
• Mottet C, Vader J-P, Felley C, et al.; EPACT II Study Group. Appropriate management of special situations in Crohn’s disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis. 2009 Dec;3(4):257–263. DOI:10.1016/j.crohns.2009.03.008.
   PubMed Web of Science ®Google Scholar
• Wormser D, Chen DM, Brunetta PG, et al. Cumulative oral corticosteroid use increases risk of glucocorticoid-related adverse events in patients with newly diagnosed pemphigus. J Am Acad Dermatol. 2017 Aug;77(2):379–381. DOI:10.1016/j.jaad.2017.04.1116.
   PubMed Web of Science ®Google Scholar
• Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993 Jun;45(6):953–1040. Review. Erratum in: Drugs 1993 Sep;46(3):377. Drugs. 1993 Sep;46(3):377. DOI:10.2165/00003495-199345060-00007.
   PubMed Web of Science ®Google Scholar
• Santana AL, Felsen D, Carucci JA. Interleukin-22 and cyclosporine in aggressive cutaneous squamous cell carcinoma. Dermatol Clin. 2017 Jan;35(1):73–84. Review. DOI:10.1016/j.det.2016.07.003.
   PubMed Web of Science ®Google Scholar
• Behnam SM, Behnam SE, Koo JY. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol. 2005 Mar-Apr;4(2):189–194. Review.
   PubMedGoogle Scholar
• Muellenhoff MW, Koo JY. Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. J Dermatolog Treat. 2012 Aug;23(4):290–304. DOI:10.3109/09546634.2011.590792.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Ishak RS, Saibeni S, et al. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013 Oct;45(2):202–210. Review. DOI:10.1007/s12016-012-8351-x.
   PubMed Web of Science ®Google Scholar
• Del Puerto C, Navarrete-Dechent CP, Carrasco-Zuber JE, et al. Intralesional methotrexate as an adjuvant treatment for pyoderma gangrenosum: a case report. Indian J Dermatol Venereol Leprol. 2017 Mar-Apr;83(2):277. DOI:10.4103/0378-6323.186497.
   PubMed Web of Science ®Google Scholar
• Chatzinasiou F, Polymeros D, Panagiotou M, et al. Generalized pyoderma gangrenosum associated with ulcerative colitis: successful treatment with infliximab and azathioprine. Acta Dermatovenerol Croat. 2016 Apr;24(1):83–85.
   PubMed Web of Science ®Google Scholar
• Sardar P, Guha P, Das NK, et al. Ulcerative pyoderma gangrenosum in mixed connective tissue disorder: a rare association and role of azathioprine in the management. Indian J Dermatol. 2011 Sep-Oct;56(5):600–602. DOI:10.4103/0019-5154.87172.
   PubMedGoogle Scholar
• Parakkal D, Sifuentes H, Semer R, et al. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol. 2011 Nov;23(12):1150–1156. DOI:10.1097/MEG.0b013e32834bb90a.
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011 Jan;9(1):36–41.e1. DOI:10.1016/j.cgh.2010.09.016.
   PubMed Web of Science ®Google Scholar
• Na R, Laaksonen MA, Grulich AE, et al. Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: a population-based cohort study in Australia. Br J Haematol. 2016 Aug;174(4):550–562. DOI:10.1111/bjh.14083.
   PubMed Web of Science ®Google Scholar
• Na R, Laaksonen MA, Grulich AE, et al. High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: a population-based cohort study. J Am Acad Dermatol. 2016 Jun;74(6):1144–1152.e6. DOI:10.1016/j.jaad.2015.12.044.
   PubMed Web of Science ®Google Scholar
• Lennard L. Clinical implications of thiopurine methyltransferase–optimization of drug dosage and potential drug interactions. Ther Drug Monit. 1998 Oct;20(5):527–531. Review.
   PubMed Web of Science ®Google Scholar
• Armstrong VW, Shipkova M, Von Ahsen N, et al. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit. 2004 Apr;26(2):220–226. Review.
   PubMed Web of Science ®Google Scholar
• Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord. 2003;3 Suppl 1(Suppl 1):S30–S38.
   PubMedGoogle Scholar
• Li J, Chong AH, Green J, et al. Mycophenolate use in dermatology: a clinical audit. Australas J Dermatol. 2013 Nov;54(4):296–302. DOI:10.1111/ajd.12042.
   PubMed Web of Science ®Google Scholar
• Li J, Kelly R. Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol. 2013 Oct;69(4):565–569. DOI:10.1016/j.jaad.2013.05.028.
   PubMed Web of Science ®Google Scholar
• Eaton PA, Callen JP. Mycophenolate mofetil as therapy for pyoderma gangrenosum. Arch Dermatol. 2009 Jul;145(7):781–785. DOI:10.1001/archdermatol.2009.57.
   PubMedGoogle Scholar
• Park H. The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room. J Clin Aesthet Dermatol. 2011;4:18–27.
   PubMedGoogle Scholar
• George L, Hamann I, Chen K, et al. An analysis of the dermatological uses of mycophenolate mofetil in a tertiary hospital. J Dermatolog Treat. 2013. DOI:10.3109/09546634.2013.860419.
   Web of Science ®Google Scholar
• Fukuhara K, Urano Y, Kimura S, et al. Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone. Br J Dermatol. 1998 Sep;139(3):556–558.
   PubMed Web of Science ®Google Scholar
• Teasley LA, Foster CS, Baltatzis S. Sclerokeratitis and facial skin lesions: a case report of pyoderma gangrenosum and its response to dapsone therapy. Cornea. 2007 Feb;26(2):215–219.
   PubMed Web of Science ®Google Scholar
• Galun E, Flugelman MY, Rachmilewitz D. Pyoderma gangrenosum complicating ulcerative colitis: successful treatment with methylprednisolone pulse therapy and dapsone. Am J Gastroenterol. 1986 Oct;81(10):988–989.
   PubMed Web of Science ®Google Scholar
• Ward KE, McCarthy MW. Dapsone-induced methemoglobinemia. Ann Pharmacother. 1998 May;32(5):549–553. Review.
   PubMed Web of Science ®Google Scholar
• Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014 Feb;164(4):469–480. Epub 2013 Dec 28. Review. DOI:10.1111/bjh.12665.
   PubMed Web of Science ®Google Scholar
• Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006 Feb;54(2):258–265. Review.
   PubMed Web of Science ®Google Scholar
• Foley CC, Laing M. Paraneoplastic pyoderma gangrenosum successfully treated with minocycline and low-dose steroids. J Eur Acad Dermatol Venereol. 2015 Jan;29(1):184–185. DOI:10.1111/jdv.12384.
   PubMed Web of Science ®Google Scholar
• Reynolds NJ, Peachey RD. Response of atypical bullous pyoderma gangrenosum to oral minocycline hydrochloride and topical steroids. Acta Derm Venereol. 1990;70(6):538–539.
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Murota H, Goto H, et al. Pyoderma gangrenosum and annular erythema associated with Sjögren’s syndrome controlled with minocycline. J Dermatol. 2015 Aug;42(8):834–836. DOI:10.1111/1346-8138.12897.
   PubMed Web of Science ®Google Scholar
• Miralles ES, Nuñez M, Pérez B, et al. Minocycline hydrochloride hyperpigmentation complicating treatment of pyoderma gangrenosum. J Dermatol. 1994 Dec;21(12):965–967.
   PubMedGoogle Scholar
• Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006 Apr;55(4):505–509.
   PubMed Web of Science ®Google Scholar
• Mooij JE, Van Rappard DC, Mekkes JR. Six patients with pyoderma gangrenosum successfully treated with infliximab. Int J Dermatol. 2013 Nov;52(11):1418–1420. DOI:10.1111/j.1365-4632.2011.05201.x.
   PubMedGoogle Scholar
• Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003 Aug;98(8):1821–1826.
   PubMed Web of Science ®Google Scholar
• Tada M, Nakanishi T, Hirata C, et al. Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis. Mod Rheumatol. 2010 Dec;20(6):598–601. DOI:10.1007/s10165-010-0336-0.
   PubMed Web of Science ®Google Scholar
• Lecluse LL, Piskin G, Mekkes JR, et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008 Sep;159(3):527–536. Epub 2008 Jul 9. Review. DOI:10.1111/j.1365-2133.2008.08728.x.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Gurske J. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. J Am Acad Dermatol. 2005 Oct;53(4):616–622.
   PubMed Web of Science ®Google Scholar
• Smith CH, Jackson K, Bashir SJ, et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol. 2006 Jul;155(1):160–169.
   PubMed Web of Science ®Google Scholar
• Mocci G, Marzo M, Papa A, et al. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013 Nov 7;7(10):769–779. Epub 2013 Mar 1. Review. DOI:10.1016/j.crohns.2013.01.009.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: safety. Am J Gastroenterol. 2011 Sep;106(9):1594–602;quiz 1593, 1603. DOI:10.1038/ajg.2011.211.
   Web of Science ®Google Scholar
• Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005 May;152(5):1059–1061.
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn’s disease. Inflamm Bowel Dis. 2009 Jun;15(6):803–806. DOI:10.1002/ibd.20748.
   PubMed Web of Science ®Google Scholar
• Cariñanos I, Acosta MB, Domènech E. Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. Inflamm Bowel Dis. 2011 Dec;17(12):E153–E154. DOI:10.1002/ibd.21723.
   PubMed Web of Science ®Google Scholar
• Charles CA, Leon A, Banta MR, et al. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol. 2007 Oct;46(10):1095–1099.
   PubMed Web of Science ®Google Scholar
• Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S128–S134.
   PubMed Web of Science ®Google Scholar
• Pastor N, Betlloch I, Pascual JC, et al. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept). Clin Exp Dermatol. 2006 Jan;31(1):152–153.
   PubMed Web of Science ®Google Scholar
• Kowalzick L, Bertolini J, Baumann C, et al. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges. 2013 May;11(5):447–449. DOI:10.1111/ddg.12032.
   PubMed Web of Science ®Google Scholar
• Beynon C, Chin MF, Hunasehally P, et al. Successful treatment of autoimmune disease-associated pyoderma gangrenosum with the IL-1 receptor antagonist anakinra: a case series of 3 patients. J Clin Rheumatol. 2017 Apr;23(3):181–183. DOI:10.1097/RHU.0000000000000511.
   PubMed Web of Science ®Google Scholar
• Wulffraat NM. A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis. Expert Opin Drug Saf. 2015;14(12):1961–1967.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Lopalco G, Caso F, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet’s disease. Autoimmun Rev. 2015 Jan;14(1):1–9. DOI:10.1016/j.autrev.2014.08.008.
   PubMed Web of Science ®Google Scholar
• Benzaquen M, Monnier J, Beaussault Y, et al. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: effectiveness of ustekinumab. Australas J Dermatol. 2017 Jun;28. DOI:10.1111/ajd.12545
   Google Scholar
• Cosgarea I, Lovric Z, Körber A, et al. Successful treatment of refractory pyoderma gangrenosum with ustekinumab only after excision of renal cell carcinoma. Int Wound J. 2016 Oct;13(5):1041–1042. DOI:10.1111/iwj.12377.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Moćko P, Malinowska-Lipien I, et al. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn’s disease patients: a systematic review and meta-analysis. J Comp Eff Res. 2017 Jun;29. DOI:10.2217/cer-2017-0022
   Google Scholar
• Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800.
   PubMed Web of Science ®Google Scholar